Form 4: Enliven Therapeutics Director Richard A. Heyman Sells Shares

Director Richard A. Heyman of Enliven Therapeutics, Inc. reports selling 2,825 shares of common stock at a weighted average price of $27.5057.

Summary

• Richard A. Heyman, a director of Enliven Therapeutics, Inc., filed a Form 4 disclosing changes in beneficial ownership.
• On October 4, 2024, Heyman sold 2,825 shares of common stock at a weighted average price of $27.5057.
• The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on July 17, 2023.
• Following the transaction, Heyman directly owns 125,760 shares.
• Heyman also indirectly owns 37,407 shares through the Richard A. Heyman and Anne E. Daigle Trust and 27,918 shares through RAHD Capital LLC.

Sentiment

Score: 5

Explanation: The document is a neutral report of a stock sale by a company director. It doesn't inherently indicate positive or negative sentiment.

Industry Context

This filing is a routine disclosure of stock transactions by a company insider. It provides transparency to the market regarding the trading activities of key personnel.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies, ensuring transparency in insider trading.
• The Rule 10b5-1 trading plan is a common tool used by executives to avoid accusations of insider trading, similar to plans used by executives at companies like Pfizer or Moderna.

Stakeholder Impact

• The stock sale may have a minor impact on shareholders, potentially creating slight downward pressure on the stock price in the short term.

Key Dates